Diseases and vaccines

Rotavirus vaccine cost-effectiveness

Cost-effectiveness analysis of a rotavirus immunization program for the United States (1998)
Tucker A, et al. Journal of the American Medical Association. 279(17):1371-1376.
This review analyzed the cost-effectiveness of rotavirus vaccine introduction from the perspective of health care systems and society.

Cost-effectiveness of rotavirus vaccines (2005)
Walker D, Rheingans R. Expert Review Pharmacoeconomics Outcomes Research. 5(5):593-601.
 This article reviews economic evaluations of Rotarix® and RotaTeq® and offers suggestions for future analyses of cost-effectiveness.

Cost effectiveness of rotavirus vaccines and other interventions for diarrhoeal diseases: Meeting report 2006
World Health Organization (WHO)
This report from the WHO's Weekly Epidemiologic Record summarizes a meeting convened by PATH, WHO, and the US Centers for Disease Control and Prevention (CDC) on the economic burden of rotavirus disease and cost-effectiveness of vaccines. The summary outlines meeting discussions and recommendations with regard to future studies on rotavirus vaccine cost-effectiveness in developing countries.

Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: The REVEAL study (2007)
Giaquinto C, et al. Journal of Infectious Diseases. 195(S1):S36-S44.
Investigators found that rotavirus gastroenteritis incurs considerable use of health care resources and results in substantial costs for families of patients and employers. Routine rotavirus vaccination could
significantly reduce the related economic burden.

Evaluaciónde costo-efectividad de la vacuna anti-rotavirus en Chile (2006)
Constenla D, O'Ryan M, Navarrete M, Antil L, Rheingans R. Revista Médica de Chile. 134(6):697-688.
This article outlines an economic model that determined rotavirus vaccination is a cost-effective intervention that can effectively reduce the disease burden and healthcare costs of rotavirus gastroenteritis.

Guidelines for estimating the economic burden of diarrheal disease with focus on assessing the costs of rotavirus diarrhea (2002)
World Health Organization (WHO) Department of Immunization, Vaccines, and Biologicals. WHO/IVB/05.10
WHO developed these guidelines to present a method for determining the costs associated with diarrheal disease in children under 5 years of age.

Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam (2005)
Fischer T, Anh D, Antil L, et al. Journal of Infectious Diseases. 192:1720-1726.
This study estimated economic burden and the vaccination cost-effectiveness ratio to determine potential reductions in health care costs associated with rotavirus-specific diarrhea.

Health economics of universal rotavirus vaccination in Latin America & Caribbean (revised 2005)
 Rheingans R, Constenla D, Eibensteiner L.
This presentation from the Sixth International Rotavirus Symposium discussed the benefits of investing in rotavirus vaccine introduction.

Innovative Financing for Human Development (2006)
Affolder R, Lob-Levyt J. Lancet; 367(9514):885–887.

Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries (2007; abstract only)
Rheingans R, et al. Pan American Journal of Public Health. 21(4).
Investigators developed a model using epidemiological evidence, country-specific cost estimates, and vaccine efficacy data to estimate the cost-effectiveness of rotavirus vaccination and determined that it would reduce health care expenses and disease burden associated with rotavirus gastroenteritis.

Rotavirus diarrhea disease burden in Peru: The need for a rotavirus vaccine and its potential cost savings (2001)
Ehrenkranz P, Lanata C, Penny M, et al. Pan American Journal of Public Health. 10(4):240-248.
 This paper explores the relationship of disease burden to the cost-savings that may be achieved with vaccine introduction.

Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine (2007)
Isakbaeva E, et al. Vaccine. 25(2):373-380.
Investigators estimated the costs related to rotavirus disease in Uzbekistan and determined that a vaccine would be cost-effective, while also drastically reducing hospitalizations and deaths.